FDA approves Alhemo® as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B (HA/HB) without inhibitors – PR Newswire

FDA approves Alhemo® as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B (HA/HB) without inhibitors  PR NewswireEuropean regulatory authority adopts positive opinion for Novo Nordisk’s Alhemo® (concizumab), recommending label expansion to treat haemophilia A and B without inhibitors  Yahoo FinanceFDA approves concizumab-mtci for hemophilia A/B without inhibitors in patients 12 years and older  Contemporary PediatricsNovo Nordisk’s Alhemo Recommended for Expanded Use in Europe for Haemophilia A and B  Insider MonkeyEuropean Medicines Agency Issues Positive Opinion for Concizumab Label Update in Hemophilia  Docwire News